Can costs be measured and predicted by modeling within a cooperative clinical trials group? Economic methodologic pilot studies of the radiation therapy oncology group (RTOG) studies 90-03 and 91-04

International Journal of Radiation Oncology Biology Physics

Volumn 49, Issue 3, 2001, Pages 633-639

  Owen, Jean B ^a,h   Grigsby, Perry W ^b   Caldwell, Thomas M ^a   Konski, Andre A ^c   Johnson, Darlene J ^d   Demas, William F ^e   Movsas, Benjamin ^f   Jones, Christopher U ^g   Wasserman, Todd H ^b  

^a RADIATION THERAPY ONCOLOGY GROUP   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Toledo Radiological Associates   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e AKRON CITY HOSPITAL   (United States)

^f FOX CHASE CANCER CENTER   (United States)

^g Radiological Associates of Sacramento Medical Group Inc   (United States)

^h AMERICAN COLLEGE OF RADIOLOGY   (United States)

Author keywords

Clinical trials; Economic studies; Radiation oncology

Indexed keywords

ARTICLE; BRAIN METASTASIS; CANCER RADIOTHERAPY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; FRACTIONATION; HEAD AND NECK CARCINOMA; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; META ANALYSIS; MODEL; PREDICTION; PRIORITY JOURNAL; QUALITY CONTROL;

EID: 0035283732     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)00770-7     Document Type: Article

References (9)

1. National Cancer Institute economic conference; The integration of economic outcome measures into NCI-sponsored therapeutic trials
2. Integrating economic analysis into cancer clinical trials. The National Cancer Institute-American Society of Clinical Oncology Economics workbook
3. Economic analysis in phase III clinical cancer trials
4. A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases. A report of the Radiation Therapy Oncology Group (RTOG) 9104
5. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation, and two variants of accelerated fractionation to standard fractionation radiotherapy for head, and neck squamous cell carcinomas; First report of RTOG 9003 (Abstr.)